Reduction of Events by Darbepoetin Alfa in Heart Failure - RED-HF


Patients with systolic heart failure and anemia have worse symptoms, functional capacity, and outcomes than those without anemia. Studies on the role of erythropoietin-stimulating agents (ESAs) have been mixed and small for the most part. The current trial sought to investigate the safety and efficacy of darbepoetin alpha in patients with symptomatic systolic heart failure and anemia.